• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OptiScan’s glucose monitoring system for the ICU wins 510(k) clearance

October 18, 2017 By Sarah Faulkner

OptiScanOptiScan Biomedical said today that its OptiScanner 5000 glucose monitoring system won 510(k) clearance.

The device is the first of its kind, providing physicians with trending and tracking information to manage their patients’ blood glucose levels in surgical intensive care units.

The Hayward, Calif.-based company’s technology uses alarms to alert clinicians when patients are experiencing hyperglycemia and hypoglycemia. The bedside system is automated, updating every 15 minutes with a new measure of glucose levels from plasma, as opposed to whole blood.

The FDA clearance was supported by results from OptiScan’s pivotal trial in 160 patients from surgical intensive care units comparing the accuracy of the company’s system to the industry standard glucose measurement in the ICU.

“This clearance by FDA is incredibly gratifying for the entire OptiScan team. We, along with many other companies in the medical device space, have dedicated considerable time and effort toward the goal of bringing continuous glucose monitoring technology into the ICU. We are proud to be the first company to have achieved success in the form of a regulatory clearance by FDA,” chairman & CEO Peter Rule said in prepared remarks.

“We believe the OptiScanner 5000 is well positioned to assist clinicians to improve the management of hyperglycemia and hypoglycemia in surgical intensive care unit patients.”

“As a clinician who has had the opportunity to work directly with the OptiScanner 5000 as part of its clinical studies, I am very pleased to know that I will now be able to implement the device broadly to enhance the care I am able to deliver to those patients for whom this FDA clearance applies,” Dr. Grant Bochicchio, chief of acute and critical care surgery at the Washington University School of Medicine, added.

“There is a broad consensus in the medical community regarding the need for automated, continuous and highly accurate glucose monitoring in the ICU and my experience with the OptiScanner 5000 indicates that this device will play a critical role in delivering this enhanced level of care. I look forward to implementing this technology as soon as possible.”

The OptiScanner 5000 also has CE Mark approval in the EU.

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Hospital Care, Regulatory/Compliance Tagged With: optiscanbiomedical

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS